Kevin J. Curran

Hematology | Oncology
1275 York Ave
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Journal: Blood advances
Published: March 24, 2026

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

Journal: Nature reviews. Clinical oncology
Published: December 15, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

IL7-Receptor-Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia.

IL7-Receptor-Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia.

Journal: Nature communications
Published: August 20, 2025

Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies.

Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: July 17, 2025

Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.

Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.

Journal: The Lancet. Haematology
Published: June 24, 2025

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

Journal: Blood advances
Published: June 20, 2025

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

Journal: Blood advances
Published: May 06, 2025

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Journal: Blood advances
Published: April 29, 2025

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Journal: Blood advances
Published: April 14, 2025

CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.

CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.

Journal: Blood
Published: April 14, 2025
Showing 1-12 of 77

Last Updated: 09/26/2026